Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 2009 Nov;158(Suppl 1):S208–S209. doi: 10.1111/j.1476-5381.2009.00506_5.x

Caspases (E.C. 3.4.22.-)

PMCID: PMC2884559

Overview: Caspases, which derive their name from Cysteine ASPartate-specific proteASES, include at least two families; initiator caspases (caspases 2, 8, 9 and 10), which are able to hydrolyse and activate a second family of effector caspases (caspases 3, 6 and 7), which themselves are able to hydrolyse further cellular proteins to bring about programmed cell death. Caspases are heterotetrameric, being made up of two pairs of subunits, generated by a single gene product, which is proteolysed to form the mature protein. Members of the mammalian inhibitors of apoptosis proteins (IAP) are able to bind the procaspases, thereby preventing maturation to active proteinases.

Nomenclature Caspase 1 Caspase 2 Caspase 3 Caspase 4
Other names CASP1, interleukin-1β convertase, IL-1BC, interleukin-1 β-converting enzyme, IL-1 β-converting enzyme, ICE, p45 CASP2, ICH-1 protease, neural precursor cell expressed developmentally down-regulated protein 2, NEDD-2 CASP3, apopain, cysteine protease CPP32, Yama protein, SREBP cleavage activity 1, SCA-1 CASP4, ICH-2 protease, TX protease, ICE(rel)-II,
Subunits Caspase-1 subunit p20; Caspase-1 subunit p10 Caspase-2 subunit p18; Caspase-2 subunit p13; Caspase-2 subunit p12 Caspase-3 subunit p17; Caspase-3 subunit p12 Caspase-4 subunit 1; Caspase-4 subunit 2
EC 3.4.22.36 3.4.22.55 3.4.22.56 3.4.22.57
Ensembl ID ENSG00000137752 ENSG00000106144 ENSG00000164305 ENSG00000196954
Substrates Pro-caspase 4, pro-interleukin-1β, D4-GD1, parkin Pro-caspase 7, caspase 3, PARP, ICAD, Rb, PKCδ, Huntingtin Pro-caspase 1
Endogenous activators Caspase 8, caspase 9, caspase 10, GrB
Activators PAC1 (Putt et al., 2006), PETCM (Jiang et al., 2003)
Selective inhibitors Z-YVAD-FMK (Avivi-Green et al., 2002) Z-VDVAD-FMK (Gamen et al., 2000) AZ10417808 (Scott et al., 2003), Z-DEVD-FMK (Brockstedt et al., 1998), Z-DQMD-FMK (Izban et al., 2001)

CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE, ENSG00000204397) shares sequence similarity with some of the caspases.

Nomenclature Caspase 5 Caspase 6 Caspase 7 Caspase 8
Other names CASP5, ICH-3 protease, TY protease, ICE(rel)-III CASP6, apoptotic protease Mch-2 CASP7, ICE-like apoptotic protease 3, ICE-LAP3, apoptotic protease Mch-3, CMH-1 CASP8, CE-like apoptotic protease 5, MORT1-associated CED-3 homolog, MACH, FADD-homologous ICE/CED-3-like protease, FADD-like ICE, FLICE, apoptotic cysteine protease, apoptotic protease Mch-5, CAP4
Subunits Caspase-5 subunit p20; Caspase-5 subunit p10 Caspase-6 subunit p18; Caspase-6 subunit p11 Caspase-7 subunit p20; Caspase-7 subunit p11 Caspase-8 subunit p18; Caspase-8 subunit p10
EC 3.4.22.58 3.4.22.59 3.4.22.60 3.4.22.61
Ensembl ID ENSG00000137757 ENSG00000138794 ENSG00000165806 ENSG00000064012
Substrates Pro-caspase 7, caspase 3, PARP, ICAD, Rb, PKCδ, Huntingtin Pro-caspase 3, pro-caspase 7, caspase 8, Bid, FLIP, pro-caspase 6
Endogenous activators Caspase 8, caspase 9, caspase 10, GrB Caspase 8, caspase 9, caspase 10, GrB DISC
Selective inhibitors Z-WEHD-FMK (Naito et al., 2002) Z-VEID-FMK (Ruchaud et al., 2002) Z-IETD-FMK (Gregoli and Bondurant, 1999)
Nomenclature Caspase 9 Caspase 10 Caspase 14
Other names ICE-like apoptotic protease 6, ICE-LAP6, apoptotic protease Mch-6, apoptotic protease-activating factor 3, APAF-3 CASP10, ICE-like apoptotic protease 4, apoptotic protease Mch-4, FAS-associated death domain protein interleukin-1B-converting enzyme 2, FLICE2 CASP14
Subunits Caspase-9 subunit p35; Caspase-9 subunit p10 Caspase-10 subunit p23/17; Caspase-10 subunit p12 Caspase-14 subunit p19; Caspase-14 subunit p10
EC 3.4.22.62 3.4.22.63 3.4.22.-
Ensembl ID ENSG00000132906 ENSG00000003400 ENSG00000105141
Substrates Pro-caspase 3, pro-caspase 7, caspase 9, pro-caspase 6, PARP Pro-caspase 3, pro-caspase 7, caspase 10, pro-caspase 6
Endogenous activators DISC
Selective inhibitors Z-LEHD-FMK (Mocanu et al., 2000)

Glossary

Abbreviations:

AZ10417808

2-([3,4-dichlorophenyl]amino)-1,4-dihydro-6-nitro-4-oxo-N-2-propenyl-8-quinazolinecarboxamide

PAC1

4-(phenylmethyl)-1-piperazineacetic acid ([2-hydroxy-3-{2-propenyl}phenyl]methylene)hydrazide

PETCM

1-(trichloromethyl)-2-(4-pyridine)ethanol

Z-DEVD-FMK

benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone

Z-DQMD-FMK

benzyloxycarbonyl-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone

Z-LEHD-FMK

benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone

Z-VDVAD-FMK

benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethylketone

Z-VEID-FMK

benzyloxycarbonyl-Val-Glu(OMe)-Ile-Asp(OMe)-fluoromethylketone

Z-VYAD-FMK

benzyloxycarbonyl-Tyr-Val-Ala-Asp(OMe)-fluoromethylketone

Z-WEHD-FMK

benzyloxycarbonyl-Trp-Glu(OMe)-His-Asp(OMe)-fluoromethylketone

Further Reading

Festjens N, Cornelis S, Lamkanfi M, Vandenabeele P (2006). Caspase-containing complexes in the regulation of cell death and inflammation. Biol Chem387: 1005–1016.

Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009). The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol10: 241–247.

Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV (2008). Caspase activity modulators as anticancer agents. Anticancer Agents Med Chem8: 322–341.

Taylor RC, Cullen SP, Martin SJ (2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol9: 231–241.

References

  1. Avivi-Green C, et al. J Nutr. 2002;132:1812–1818. doi: 10.1093/jn/132.7.1812. [DOI] [PubMed] [Google Scholar]
  2. Brockstedt E, et al. J Biol Chem. 1998;273:28057–28064. doi: 10.1074/jbc.273.43.28057. [DOI] [PubMed] [Google Scholar]
  3. Gamen S, et al. Exp Cell Res. 2000;258:223–235. doi: 10.1006/excr.2000.4924. [DOI] [PubMed] [Google Scholar]
  4. Gregoli PA, Bondurant MC. J Cell Physiol. 1999;178:133–143. doi: 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  5. Izban KF, et al. Mod Pathol. 2001;14:297–310. doi: 10.1038/modpathol.3880306. [DOI] [PubMed] [Google Scholar]
  6. Jiang X, et al. Science. 2003;299:223–226. doi: 10.1126/science.1076807. [DOI] [PubMed] [Google Scholar]
  7. Mocanu MM, et al. Br J Pharmacol. 2000;130:197–200. doi: 10.1038/sj.bjp.0703336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Naito T, et al. Nucleic Acids Res Suppl 2. 2002:241–242. [PubMed] [Google Scholar]
  9. Putt KS, et al. Nat Chem Biol. 2006;2:543–550. doi: 10.1038/nchembio814. [DOI] [PubMed] [Google Scholar]
  10. Ruchaud S, et al. EMBO J. 2002;21:1967–1977. doi: 10.1093/emboj/21.8.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Scott CW, et al. J Pharmacol Exp Ther. 2003;304:433–440. doi: 10.1124/jpet.102.039651. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES